S&P 500
(0.03%) 5 250.26 points
Dow J
(-0.01%) 39 757 points
Nasdaq
(-0.16%) 16 374 points
Oil
(1.77%) $82.79
Gas
(1.69%) $1.747
Gold
(1.34%) $2 242.30
Silver
(0.67%) $24.92
Platinum
(1.18%) $920.45
USD/EUR
(0.30%) $0.926
USD/NOK
(0.76%) $10.85
USD/GBP
(0.08%) $0.792
USD/RUB
(0.18%) $92.60

Realtime updates for MorphoSys AG [MOR]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
87.50%
return 4.16%
SELL
12.50%
return 3.35%
Last Updated28 Mar 2024 @ 13:14

-0.17% $ 18.11

BUY 61704 min ago

@ $17.43

Issued: 14 Feb 2024 @ 15:57


Return: 3.90%


Previous signal: Feb 14 - 10:23


Previous signal: Sell


Return: 0.29 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 13:14):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for MorphoSys AG

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States...

Stats
Today's Volume 149 481
Average Volume 2.13M
Market Cap 2.73B
EPS $0 ( 2024-03-13 )
Next earnings date ( $-0.510 ) 2024-05-01
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -12.07
ATR14 $0.00500 (0.03%)

Volume Correlation

Long: 0.14 (neutral)
Short: 0.97 (very strong)
Signal:(50.052) Expect same movement, but be aware

MorphoSys AG Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MorphoSys AG Correlation - Currency/Commodity

The country flag -0.71
( moderate negative )
The country flag -0.57
( weak negative )
The country flag 0.00
( neutral )
The country flag -0.75
( moderate negative )
The country flag 0.00
( neutral )
The country flag -0.26
( neutral )

MorphoSys AG Financials

Annual 2023
Revenue: $238.28M
Gross Profit: $179.92M (75.51 %)
EPS: $-1.380
Q4 2023
Revenue: $59.08M
Gross Profit: $44.52M (75.36 %)
EPS: $1.280
Q3 2023
Revenue: $63.80M
Gross Profit: $48.70M (76.33 %)
EPS: $-0.880
Q2 2023
Revenue: $53.17M
Gross Profit: $45.46M (85.51 %)
EPS: $-0.540

Financial Reports:

No articles found.

MorphoSys AG

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators